Despite these near-term challenges, we maintain our positive long-term outlook for Lonza thanks to strong demand for outsourced manufacturing of biologics and cell and gene therapies. We maintain ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to helping customers deliver ...

Santagostino, who was announced in the role in late October, joined AGC Biologics from the pharmaceutical manufacturing ...

Under new leadership, AGC Biologics will be "Your friendly CDMO expert" SEATTLE, WA / ACCESSWIRE / October 28, 2024 /AGC ...

Collaboration underscores Lonza's commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat's ...

Lonza Group AG现在的股价报62.89 Lonza Group AG的股票在哪间交易所挂牌交易？ Lonza Group AG的股票在OTC市场挂牌交易。 Lonza Group AG的股票代码是什么？ Lonza Group AG的股票代码是“LZAGY。” Lonza Group AG有分红吗？当前的股息收益率是多少？ 的股息收益率是0.20%。 Lonza Group AG ...

We look forward to supporting BigHat with every step in the ADC development and manufacturing process under the Lonza umbrella.” Jean-Christophe Hyvert, President, Biologics, Lonza, added: “We are ...